Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Salivary lactoferrin as biomarker for Alzheimer’s disease: brain-immunity interactions

dc.contributor.authorBermejo-Pareja, Félix
dc.contributor.authorSer, Teodoro del
dc.contributor.authorValentí, Meritxell
dc.contributor.authorFuente del Rey, Mónica de la
dc.contributor.authorBartolomé, Fernando
dc.contributor.authorCarro, Eva
dc.date.accessioned2023-06-16T15:24:23Z
dc.date.available2023-06-16T15:24:23Z
dc.date.issued2020-06-16
dc.description.abstractObjective: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer’s disease (sAD).1 We also will discuss if such Lf decrease could be due to a downregulation of the sAD associated systemic immunity. Background: Several non-neurological alterations have been described in sAD, mainly in skin, blood cell, and immunological capacities. We reviewed briefly the main pathophysiological theories of sAD (amyloid cascade, tau, unfolder protein tau, and amyloid deposits) emphasizing the most brain based hypotheses such as the updated tau-related neuron skeletal hypothesis; we also comment on the systemic theories that emphasize the fetal origin of the complex disorders that include the low inflammatory and immunity theories of sAD. New/updated hypothesis: Lf has important anti-infectious and immunomodulatory roles in health and disease. We present the hypothesis that the reduced levels of saliva Lf could be an effect of immunological disturbances associated to sAD. Under this scenario, two alternative pathways are possible: first, whether sAD could be a systemic disorder (or disorders) related to early immunological and low inflammatory alterations; second, if systemic immunity alterations of sAD manifestations could be downstream of early sAD brain affectations. Major challenges for the hypothesis: The major challenge of the Lf as early sAD biomarker would be its validation in other clinical and population-based studies. It is possible the decreased salivary Lf in early sAD could be related to immunological modulation actions, but other different unknown mechanisms could be the origin of such reduction. Linkage to other major theories:This hypothesis is in agreement with two physiopathological explanations of the sAD as a downstream process determined by the early lesions of the hypothalamus and autonomic vegetative system (neurodegeneration), or as a consequence of low neuroinflammation and dysimmunity since the early life aggravated in the elderly (immunosenescence)
dc.description.departmentDepto. de Genética, Fisiología y Microbiología
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Ciencias Biológicas
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipComunidad de Madrid
dc.description.sponsorshipInstituto de Salud Carlos III (Madrid, España)
dc.description.sponsorshipCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)
dc.description.sponsorshipFederación Española de Enfermedades Raras (FEDER)
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/62341
dc.identifier.doi10.1002/alz.12107
dc.identifier.issn1552-5260, ESSN 1552-5279
dc.identifier.officialurlhttps://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12107
dc.identifier.urihttps://hdl.handle.net/20.500.14352/6594
dc.issue.number8
dc.journal.titleAlzheimer's & Dementia
dc.language.isoeng
dc.page.final1204
dc.page.initial1196
dc.publisherWiley
dc.relation.projectIDNEUROMETAB-CM (S2017/BMD-3700); CIBERNED(PI2016/01) )
dc.relation.projectID(FIS15/00780, FIS18/00118)
dc.relation.projectID(PI2016/01)
dc.rightsAtribución-NoComercial 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/es/
dc.subject.cdu612.8
dc.subject.jel616.894-053.9
dc.subject.keywordAlzheimer’s disease
dc.subject.keywordAmyloid
dc.subject.keywordBiomarkers
dc.subject.keywordBrain-immunity interactions
dc.subject.keywordHypothalamus
dc.subject.keywordImmunity
dc.subject.keywordLactoferrin
dc.subject.keywordSaliva
dc.subject.ucmNeurociencias (Biológicas)
dc.subject.unesco2490 Neurociencias
dc.titleSalivary lactoferrin as biomarker for Alzheimer’s disease: brain-immunity interactions
dc.typejournal article
dc.volume.number16
dspace.entity.typePublication

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Bermejo Pareja, Félix. 2020. Salivary lactoferrin as biomarker.pdf
Size:
441.78 KB
Format:
Adobe Portable Document Format

Collections